| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 0.0 | 2.4 | 3.2 |
| Other income | 0.0 | 0.1 | 0.2 |
| Total income | 0.0 | 2.5 | 3.5 |
| Profit before exceptional items & tax | -7.8 | -3.3 | -1.1 |
| Profit before tax | -7.8 | -3.3 | -1.1 |
| Net profit | -5.9 | -2.3 | -1.5 |
| Operating margin | 0.0% | -132.0% | -31.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
Source
Read the filing ↗
BSE results filing, NSE: VISTAPH. Figures extracted from the filing.
Vista Pharmaceuticals Ltd: key numbers
- Share price
- ₹6.52
- Market cap
- ₹40.13 Cr
- Revenue (annual)
- ₹5.40 Cr
- Net profit (annual)
- ₹-12.06 Cr
- P/E (TTM)
- -3.4×Sector 50.4×
- Promoter holding
- 21.19%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vista Pharmaceuticals Ltd
All →
10:45 IST
BSE
Management Change
Vista Pharmaceuticals Management Change
Vista Pharmaceuticals Ltd announced the resignation of Mrs. Barkha Jain as Company Secretary and Compliance Officer, effective September 4, 2026.
15:30 IST
BSE
Financial Results
Vista Pharmaceuticals Q1 FY27 Results: Net Loss of ₹1 Cr, Loss Narrows
Vista Pharmaceuticals Ltd reported a net loss of ₹1 Cr for Q1 FY27.
- Key figure
- Net loss ₹1 Cr